David Einhorn's position in NeuBase Therapeutics is currently worth $3.19 Million. That's 0.26% of their equity portfolio (34th largest holding). The investor owns 7.73% of the outstanding NeuBase Therapeutics stock. David Einhorn acquired their 2.73 Million shares between 2019 and 2021. So far they never sold any shares in the company. The investor's estimated purchase price is $15.5 Million, resulting in a loss of 79%.